Cancer vaccine - Merck & Co/Vical

Drug Profile

Cancer vaccine - Merck & Co/Vical

Alternative Names: V 930; V932

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Merck & Co; Vical
  • Developer Merck & Co
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 03 Dec 2008 Phase I development is ongoing in USA
  • 10 Nov 2005 Phase-I clinical trials in Cancer in USA (unspecified route)
  • 06 Oct 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top